Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CATHERINE M CRETICOS

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1356370233
CMS profile
15551
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$76,544.47

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $43,592.34 70
ViiV Healthcare Company $32,617.03 87
Merck Sharp & Dohme LLC $163.35 8
Theratechnologies Inc. $81.30 3
Napo Pharmaceuticals Inc $36.99 2
Lundbeck LLC $22.12 1
ABBVIE INC. $16.91 1
Otsuka America Pharmaceutical, Inc. $14.43 1

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CATHERINE M CRETICOS

NPI 1356370233 · CMS profile ID 15551

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356370233?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CATHERINE M CRETICOS, NPI 1356370233, CMS profile ID 15551. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356370233?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CATHERINE M CRETICOS, NPI 1356370233, CMS profile ID 15551. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356370233?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CATHERINE M CRETICOS, NPI 1356370233, CMS profile ID 15551, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356370233?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $76,544.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $18.1909/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112753860 CMS
Gilead Sciences, Inc. $0.4509/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820097 CMS
Gilead Sciences, Inc. $24.5009/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820099 CMS
ViiV Healthcare Company $31.3209/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112734089 CMS
ViiV Healthcare Company $45.8809/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112746169 CMS
ViiV Healthcare Company $11.9909/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112770886 CMS
ViiV Healthcare Company $58.2309/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112805021 CMS
ViiV Healthcare Company $15.0009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112822361 CMS
ViiV Healthcare Company $44.0009/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112743255 CMS
ViiV Healthcare Company $261.0609/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112828697 CMS
ViiV Healthcare Company $25.0609/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112717056 CMS
ViiV Healthcare Company $17.4809/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112724984 CMS
ViiV Healthcare Company $12.2409/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112727189 CMS
ViiV Healthcare Company $4.0909/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112762188 CMS
ViiV Healthcare Company $0.3109/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112817733 CMS
ViiV Healthcare Company $650.0009/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112799228 CMS
Gilead Sciences, Inc. $29.7809/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820095 CMS
Gilead Sciences, Inc. $885.0009/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133607786 CMS
ViiV Healthcare Company $47.2909/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112763556 CMS
Napo Pharmaceuticals Inc $20.8909/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147973419 CMS
ViiV Healthcare Company $47.2608/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112801073 CMS
ViiV Healthcare Company $28.2908/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112755126 CMS
ViiV Healthcare Company $2.0208/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112727927 CMS
Gilead Sciences, Inc. $13.5408/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820093 CMS
Gilead Sciences, Inc. $14.5808/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820091 CMS
Merck Sharp & Dohme LLC $18.9308/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625350 CMS
Gilead Sciences, Inc. $2,950.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133607772 CMS
Gilead Sciences, Inc. $124.3308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820089 CMS
Gilead Sciences, Inc. $422.2908/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868482 CMS
ViiV Healthcare Company $19.8008/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112807419 CMS
ViiV Healthcare Company $23.4008/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112826687 CMS
Gilead Sciences, Inc. $29.3108/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820087 CMS
ViiV Healthcare Company $17.9108/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112715388 CMS
Lundbeck LLC $22.1208/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145907571 CMS
ViiV Healthcare Company $29.7307/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112783426 CMS
Merck Sharp & Dohme LLC $19.2707/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141919036 CMS
Gilead Sciences, Inc. $28.6207/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820085 CMS
Gilead Sciences, Inc. $0.4707/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820081 CMS
Gilead Sciences, Inc. $31.2407/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820083 CMS
ViiV Healthcare Company $6.1207/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112809501 CMS
ABBVIE INC. $16.9107/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103514876 CMS
ViiV Healthcare Company $18.2807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112746573 CMS
ViiV Healthcare Company $2.4407/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112759256 CMS
ViiV Healthcare Company $0.4407/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112806405 CMS
ViiV Healthcare Company $19.9607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112793440 CMS
ViiV Healthcare Company $14.8207/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112805405 CMS
ViiV Healthcare Company $6.2107/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112736201 CMS
Merck Sharp & Dohme LLC $10.8506/13/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625447 CMS
ViiV Healthcare Company $20.5306/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112764202 CMS
Gilead Sciences, Inc. $3,890.0006/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133599823 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,840.41 102
PY2020 $43,913.99 33
PY2021 $35,551.87 53
PY2022 $50,559.72 124
PY2023 $40,985.35 139
PY2024 $76,544.47 173
PY2025 $44,734.75 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $96,927.03 29
PY2024 Principal investigator $126,454.54 30
PY2023 Principal investigator $153,940.60 24
PY2022 Principal investigator $47,124.81 18
PY2021 Principal investigator $458,371.80 49
PY2020 Principal investigator $192,439.54 36
PY2019 Recipient $1,873.48 20
PY2019 Principal investigator $263,063.85 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $668.00 12/16/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218658
Principal investigator 1 ViiV Healthcare Company $5,599.74 11/25/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318133
Principal investigator 1 Gilead Sciences, Inc. $1,526.00 11/18/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218648
Principal investigator 1 ABBVIE INC. $1,558.20 11/04/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520083
Principal investigator 1 ViiV Healthcare Company $3,003.61 10/28/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318135
Principal investigator 1 Gilead Sciences, Inc. $5,056.00 10/21/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218638
Principal investigator 1 ABBVIE INC. $2,115.00 10/09/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202514165
Principal investigator 1 ViiV Healthcare Company $11,483.86 09/23/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318137
Principal investigator 1 Gilead Sciences, Inc. $2,194.00 09/16/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218629
Principal investigator 1 ViiV Healthcare Company $2,707.91 08/26/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318129
Principal investigator 1 Gilead Sciences, Inc. $4,253.00 08/19/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218620
Principal investigator 1 ABBVIE INC. $1,433.60 08/05/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202501556
Principal investigator 1 Gilead Sciences, Inc. $624.00 07/22/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218596
Principal investigator 1 Gilead Sciences, Inc. $2,727.00 07/22/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218606
Principal investigator 1 ViiV Healthcare Company $1,965.95 07/22/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318117
Principal investigator 1 Gilead Sciences, Inc. $420.00 07/08/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218577
Principal investigator 1 Gilead Sciences, Inc. $440.00 07/08/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218587
Principal investigator 1 ViiV Healthcare Company $4,626.91 06/19/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULT No dispute reported 06/30/2026 1190318131
Principal investigator 1 Gilead Sciences, Inc. $2,402.00 06/17/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218569
Principal investigator 1 Gilead Sciences, Inc. $2,402.00 05/20/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218558
Principal investigator 1 ABBVIE INC. $1,558.20 05/07/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202483537
Principal investigator 1 Gilead Sciences, Inc. $4,063.00 04/22/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218547
Principal investigator 1 ABBVIE INC. $1,190.70 04/03/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202472661
Principal investigator 1 Gilead Sciences, Inc. $7,701.00 03/18/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218540
Principal investigator 1 ABBVIE INC. $1,190.70 03/07/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202460306
Principal investigator 1 Gilead Sciences, Inc. $12,430.00 02/19/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218529
Principal investigator 1 ABBVIE INC. $1,190.70 02/06/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202447238
Principal investigator 1 Gilead Sciences, Inc. $8,514.00 01/22/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229218519
Principal investigator 1 ABBVIE INC. $1,881.95 01/02/2025 Non-covered Recipient Entity
HOWARD BROWN HEALTH CENTER
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202433820